Leo Pharma goes head to head with Janssen in new psoriasis trial

Leo Pharma will test its psoriasis drug Kyntheum against Janssen's Tremfya, thereby also testing new-generation biologic treatments for psoriasis.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

In a new clinical trial, Danish pharmaceutical company Leo Pharma tries to get wind in the sails of the firm's first biologic treatment, Kyntheum.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading